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The lysosomal storage disorders share one common characteristic: the accumulation of a particular substrate inside the lysosome. Each disorder in this group is caused either by the deficiency of a lysosomal enzyme responsible for one step of the degradation pathway of a substrate, lack of a transporter involved in the movement of a small molecule across the lysosomal membrane, or absence of a low molecular weight activator protein required for in vivo hydrolysis of a sphingolipid. There are now more than 30 lysosomal storage diseases where the biochemical defect is well known and fully characterised. In this group, metachromatic leucodystrophy (MLD) is an autosomal recessive disorder that has been extensively studied over the past few decades.'
The overall incidence of MLD is estimated to be 1:40 0002 and the enzymatic defect associated with this disease was discovered in the 1960s. More recently, the molecular biology of MLD has been elucidated, adding to the well established biochemical knowledge. Systematic mutation analyses have been carried out in an attempt to establish genotype-phenotype relationships. A clear understanding of the molecular basis of this disease will be helpful in the genetic counselling of affected families. Allelic and non-allelic MLD variants In addition to the three clinical forms of MLD described above, which result from deficiencies in ASA activity caused by mutations in the ASA gene, three associated conditions are known, one without and two with clinical consequences. The first is allelic and is characterised by low ASA activity in healthy persons. This condition is termed ASA pseudodeficiency. It was first described in healthy relatives of MLD patients who were found to have low ASA activities similar to affected patients.'3 Persons who present this phenomenon do not store metachromatic material and have normal excretion of urinary sulphatide. A pseudodeficient allele at the ASA locus was delineated by Schaap et all4 in 1981 and was defined by Gieselmann et al'5 in 1989 after the cloning of the ASA cDNA. The allele is characterised by two mutations in the ASA gene: A--G transitions at base 1049 and base 1620. The first causes an asparagine to serine substitution (N350S), which leads to the loss of an Nglycosylation site, and the second changes the first polyadenylation signal downstream from the stop codon. The N350S mutation may occur alone and is not responsible for reduced ASA activity. ' The pseudodeficiency allele has a high frequency in general populations, which is estimated to be between 7 and 15%, 15-19 and it may coexist in families carrying an MLD associated mutation.2022 Therefore, the differential diagnosis has great importance for genetic counselling.
One non-allelic variant of MLD is multiple sulphatase deficiency (MSD). In this autosomal recessive disease at least seven different sulphatases are deficient.' These enzymes include ASA, arylsulphatase B, steroid sulphatase, and other sulphatases involved in the degradation of mucopolysaccharides. Patients show less advanced development in the presymptomatic period than that of children with late infantile MLD, and they lose the ability to sit, stand, and speak during the second year of life. Mucopolysaccharidosis-like features can be observed and death usually occurs before the end of the first decade of life,' although there is also a form with onset in the neonatal period and early death. It has been suggested that the mutation responsible for MSD is in an enzyme in the endoplasmic reticulum which performs post-translational modification of sulphatase 23 proteins. This hypothesis is based on the fact that ASA can be induced in cells of patients with MSD when certain culture conditions are used; therefore, it is likely that the structural gene for this sulphatase is intact. The gene responsible for MSD has not yet been defined. ' The other non-allelic condition is sphingolipid activator protein B (SAP-B) deficient MLD. In this case, the ASA gene is normal and the mutation is located in the gene that show signs of juvenile MLD including sulphatidurea, have a normal ASA enzyme, but abnormal ASA activity owing to the lack of SAP-B that is required for enzyme activity in vivo. The prosaposin cDNA as well as the prosaposin gene have been cloned and sequenced. [24] [25] [26] [27] Enzyme defect and diagnostic tests ASA has been purified from a variety of sources including human liver, placenta, and urine.' The enzyme has a high content of proline, aspartic acid, and glutamic acid. ASA forms a dimer at pH 4 5, but above pH 6 5 it exists as a monomer with a molecular weight of approximately 100 kDa. After purification, the enzyme consists of two non-identical subunits of different sizes depending on the source. Its active site contains two or more arginine residues. 28 The main laboratory test to diagnose MLD is the measurement of ASA activity. However, other biochemical or molecular tests have to be performed owing to the fact that low ASA activity is not comprises 507 residues, which includes a putative signal peptide of 18 residues that is removed after translocation in the endoplasmic reticulum. The amino acid sequence contains three potential N-glycosylation sites, two in exon 3 and one in exon 6.
The ASA cDNA hybridises to three mRNA species of 4 8, 3 7, and 2-1 kb on Northern blot analysis of total RNA from human fibroblasts. These species arise owing to the use of different polyadenylation signals. The first two species each account for about 30% of the total mRNA while the 2 1 kb species accounts for about 40%. After purification of polyA + RNA, the majority of the 3-7 and 4-8 kb mRNA species are lost. The 2-1 kb species is responsible for 90% of polyA + mRNA and the two larger species for about 5% each.
The structure of the ASA gene was determined by Kreysing et al" and includes about 
